Introduction
The development of multiresistance in major microbial pathogens is well-recognised; in contrust, little attention has been paid to the pathogenic potential of naturally resistant environmen tal saprophytes ' . Known originally as a phytopathogen, Burkholderia cepacia (previously Pseudomonas cepacia, P multi- The general characteristics of B. cepacia include the following: gram-negative, non-spore-forming, aerobic bacillus; motile with a respiratory metabolism and typically catalase-and oxidase-positive; various nonfluorescent pigments may be produced and poly-phydroxyalkanoates can be accumulated as reserve materials; the optimal temperature for growth is 30-35°C [7] . Recently, elegant molecular analyses have provided scientific evidence that may account for the organism's impressive versatility, including multilocus linkage disequilibrium analysis of environmental populations [8]-which suggested an extraordinarily high rate of recombination in B. cepacia relative to binary fission-and demonstration of multiple replicons and insertion sequences in type strains [9, lo] .
The natural habitats of B. cepacia have been described as soil, water and vegetation [ I l l . However, it is a common but erroneous belief that B. cepacia is a ubiquitous saprophyte sharing similar environmental habitats with Pseudomonas aeruginosa and other pseudomonads. Extensive surveillance studies have shown that culture of B. cepacia from natural sources, including soil, water and plants, or from hospitals, foodstores, restaurant salad bars and patients' homes is surprisingly difficult, with detection rates of only 1-16% [12-161.
In agricultural microbiology, ecological awareness and an increasing incidence of pesticide-resistant pathogens have led to interest in B. cepacia as a potential agent for biological control and soil decontamination. B. cepacia produces several antimicrobial agents, including pyrrolnitrins, altericidins, cepalycins and bacteriocin-like agents [17] [18] [19] [20] , that inhibit bacterial and fungal phytopathogens and suppress tobacco wilt and other plant diseases [21] . B. cepacia is also capable of degrading industrial waste and herbicides, including 2,4,5-trichlorophenoxyacetic acid (2,4,5-T), the principal ingredient of the highly potent 'agent orange' [22] . Indeed, B. cepacia has been shown to degrade 2,4,5-T in heavily contaminated soils at a rate up to 20 000-fold greater than other known degradative bacteria [23] .
In contrast to its potential agricultural benefits, B. cepacia has also emerged as a multiresistant opportunist human pathogen, leading to concern about the relationship between environmental and clinical isolates [14,24-261 and the potential hazards of releasing B. cepacia as a biological control agent [14, 24] . This review will provide an update on microbes currently described as B. cepacia, with particular focus on clinical, taxonomic and ecological issues (Table 1 ) associated with pulmonary infection in patients with cystic fibrosis (CF).
The emergence of B. cepacia as a human pathogen
Before the early 1980s, reports of human infections caused by B. cepacia were sporadic and generally restricted to hospitalised patients exposed to contaminated disinfectant and anaesthetic solutions in which this nutritionally adaptable saprophyte survives for long periods. Infections included those of soft tissues and the respiratory and urinary tracts, but bacteraemia also occurred, sometimes associated with endocarditis and septic shock [27-311. A rising incidence of B. cepacia infection was noted during the early 1980s and, although in some cases culture of B. cepacia was thought to reflect mere colonisation or contamination rather than infection [ 1 1,321, extensive analyses of USA databases of nosocomial infections confirmed a significant increase in clinically significant B. cepacia infections [33, 34] . The apparent propensity of B. cepacia to cause fatal pulmonary infections, as suggested by these analyses, is emphasised in patients with chronic granulomatous disease (CGD)-in whom B. cepacia pneumonia and septicaemia are lifethreatening [35, 36] -and in its emergence as a major pathogen in patients with CF [37-391. By the 1990s, disturbing reports also emerged of fatal cases of B. cepacia pneumonia and septicaemia in previously Is there convincing evidence to confirm that B. cepacia has pathogenic potential and is not merely a marker of pulmonary disease? Based on the success, but unpopularity, of segregation and advances in clarifying the taxonomy of the genus Burkholderia, should all B. cepacia be treated as equal? Can phenotypic or genomic markers be found which would identify highly transmissible or virulent clones? To what degree do natural environments represent a reservoir for B. cepacia and a hazard for CF patients? What hazards are associated with the development and use of B. cepacia as a biological control agent?
Could an improved understanding of the host immune response, including enhanced cytokine induction by bacterial surface components, clarify the immunopathology of B. cepacia and lead to innovative forms of immunotherapy? At present, it is not possible to forecast the clinical outcome of B. cepacia colonisation. Can host and bacterial factors responsible for initial colonisation and poor clinical outcome be identified? Recently, it has been demonstrated that CF airway epithelia contain bactericidal activity that is inhibited reversibly by high NaCl concentrations. Does this killing potential include B. cepacia and is it host or strain specific? Ultimately, the identification of bacterial and host factors associated with transmission and virulence would assist greatly in the rational design of an effective B. cepacia vaccine.
healthy individuals [40,4 I] . Community-acquired B. cepacia infections are uncommon, but the organism's pathogenic potential and the financial implications of antimicrobial therapy were recently strikingly demonstrated when an offshore oil worker developed multiple brain abscesses secondary to suppurative otitis media. Therapy involved four neurosurgical operations, an extensive period of hospitalisation and an antibiotic bill of E10K [42] .
The above case also demonstrated an interesting and unexplained variability in antibiotic susceptibility profiles that has been observed in serial B. cepacia isolates from single patients and during epidemic outbreaks [43 -461 . The mechanism responsible for variable susceptibility is unclear, but may be associated with the observation that migration of insertion sequences within the B. cepacia genome can affect the expression of genes that modulate antibiotic resistance [471.
B. cepacia and cystic fibrosis
During the last decade, the major clinical interest in B. cepacia has focused on its addition to the relatively narrow spectrum of microbial pathogens responsible for debilitating and ultimately fatal pulmonary infections in patients with CF [26, 39, 48, 49] . In the late 1980s, surveillance studies in the UK indicated a maximum prevalence of 7% [39,50-521; however, in some CF centres this later increased to approach the prevalence of 40% described in contemporary North American studies [53] . The three major issues concerning B. cepacia can be summarised as follows: 1, the clinical risk of rapid and fatal pulmonary decline, even in patients with previously mild disease; 2, patient-topatient spread of epidemic strains within and between regional CF centres and between centres in the UK and North America; and 3, the innate multiresistance of most B. cepacia isolates to available antibioticswhich deprives patients of effective antimicrobial therapy [46, 54] --combined with the failure to reduce the bacterial population in sputum and a relatively poor clinical response even when the colonising strain exhibits in-vitro susceptibility.
The clinical significance of B. cepacia in CF patients was first described in 1984 in a seminal report by Isles et al. [37] . In addition to noting the increased prevalence of B. cepacia colonisation in patients attending Toronto clinics, Isles et al. described a rapid and unexpected clinical decline, including necrotising pneumonia and bacteraemia, that occurred in c. 20% of colonised patients. This acute clinical decline is sometimes referred to as 'cepacia syndrome' [37] . It is important to note that acute clinical deterioration and bacterial spread to sites other than the lung is not observed with the other major CF pathogens, Staphylococcus a ureus, Haemop h ilus intuenzae and P aeruginosa.
The second major issue relating to B. cepacia arose in the mid 1980s as an increasing-but scientifically unproven-conviction held by some CF carers that the clustering of cases in some large North American clinics had arisen from cross-infection. At that time, an alternative explanation for clustering was the difficulty in culturing this relatively new pathogen from CF sputa [48] . As evidence, in a controlled study involving 115 North American CF centres, only 36 (3 1 YO) cultured the organism successfully from a seeded sputum specimen [55] . However, by the early 1990s, the availability of selective culture media [48] and awareness of the organism's cultural idiosyncrasies [56] indicated that regional variation in the prevalence of B. cepacia colonisation could not be explained simply by laboratory methodology. Furthermore, the development and use of bacterial fingerprinting techniques-including multilocus enzyme electrophoresis (MLEE), pyrolysis mass spectroscopy, PCRribotyping and pulsed-field gel electrophoresis (PFGE)-provided compelling evidence for personto-person spread of B. cepacia through nosocomial and social contacts (Table 2 ) [25, 37, 46, [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] and, occasionally, in the absence of proven sputum colonisation [67] . Epidemiological data also provided scientific justification for the introduction of guidelines by national CF organisations to improve personal and hospital hygiene and, more controversially, for the implementation of segregation policies to limit contact between colonised and non-colonised individuals [76] . Surveillance studies show that segregation undoubtedly reduces the incidence of B. cepacia cross-infection [38, 62, 71, 771, but the strategy has not eliminated acquisition. Furthermore, the logistic and social consequences of draconian infection control measures reminiscent of mediaeval approaches to leprosy have not been accepted universally. In particular, the need for such measures has been questioned fiercely by patients and care-givers in CF centres where intensive surveillance has not revealed a high incidence or prevalence of B. cepacia colonisation.
A pathogen or a marker of lung disease?
In the 1970s, some microbiologists and clinicians considered S. aureus to be the only true microbial pathogen in CF patients and viewed l? aeruginosa as merely a marker of disease. A similar doubt has accompanied the emergence of B. cepacia and has exacerbated the controversy surrounding segregation of colonised individuals. In discussions of any potential opportunist pathogen, it is easy to find evidence of asymptomatic carriage; even Salmonella typhi and Vibrio cholerae do not invariably exhibit pathogenicity! Clarification of the clinical relevance of B. cepacia is also thwarted by the fact that the available scientific evidence requires particularly careful analysis. There is an inclination to link bacterial transmissibility and virulence, and to categorise individual B. cepacia Thomassen et al. [57] LiPuma et al. [58] LiPuma et al. [59] Anderson et al. [60] Millar-Jones et al. [61] Govan et al. [62] Smith et al. [63] Bingen et al. [64] Corkill et al. [65] Pegues et al. [66] Johnson et al. [25] LiPuma et al. [67] Ryley et al. [68] Sun et al. [69] Revets et al. [70] Whiteford et al. [71] Pitt et al. [46] Seminal strains as either transmissible and virulent, or nontransmissible and avirulent. There is no scientific justification for this view. In epidemic outbreaks in which patients are colonised by the same strain, some patients may remain asymptomatic whilst other individuals succumb to rapid and unexpected fatal deterioration [37, 62] . In the case of transmission, epidemiological evidence has clearly identified lineages with enhanced transmissibility [25, 46, 62, 691 ; however, based on present knowledge, it cannot be stated with confidence that a strain inherently lacks the ability for epidemic spread. Furthermore, apparently 'non-transmissible' strains that have not spread even to a patient's CF sibling have been responsible for fatal infection [72] . Finally, it could be argued that transmission is not strain-dependent, but is associated with nosocomial or social opportunities for transmission. This hypothesis is certainly not supported by the behaviour of the particular B. cepacia lineage with a notorious ability to spread in CF centres in the UK [46, 62] and North America [25, 69] , referred to as the Edinburgh/Toronto lineage [69] or ET 12 intercontinental clone (multilocus enzyme electrophoresis type 12) [25] . For convenience, this particular B. cepacia lineage will be referred to as the ET12 lineage in the remainder of this review.
Some CF carers who have experienced transmission of B. cepacia amongst small numbers of their patients have argued against segregation on the grounds that no significant clinical deterioration was observed and that implementation of such draconian measures stigmatises patients and prevents valuable social contacts with other CF patients [70] . However, the hypothesis that B. cepacia is transmissible but merely a marker of pulmonary deterioration can be challenged. A recent retrospective study of the clinical status of B. cepacia-colonised adults in the 24-month period before colonisation found no difference in their lung function, number of days in hospital or outpatient visits [77] . Furthermore, in numerous case-controlled studies involving large numbers of patients, B. cepacia colonisation has been associated in some but not all patients with an accelerated decline in pulmonary function and a poor prognosis [71, [77] [78] [79] [80] [81] . Most studies have reported that the risk of clinical deterioration on acquisition of B. cepacia is increased in adult patients with severe disease . This contrasts with an epidemic outbreak of B. cepacia among children, in whom the dominant impact on respiratory function was greater in patients with better levels of respiratory function [7 I]. Explanations for the range of clinical responses associated with B. cepacia colonisation and inability to predict the clinical outcome in individual patients could include: 1, differences in strain virulence; 2, the relatively low 20% 'strike rate' of cepacia syndrome; 3, the influence of co-colonisation by other pathogens; 4, the age at which colonisation occurs; 5 , individual host immune responses; and 6, the severity of underlying CF disease.
The hypothesis that B. cepacia colonisation is merely a marker of severe lung disease is also undermined by the fact that fatalities have occurred in CF adults with mild CF disease, including individuals not already harbouring I? aeruginosa [62] . Finally, one of the most striking results from the first microbiological studies in transgenic CF mice showed that 70% of CF mice exposed to B. cepacia succumbed to more severe broncho-pulmonary infection than control animals P I - 
Potential pathogenic mechanisms of B. cepacia
Although B. cepacia produces several putative virulence determinants-including haemolysins, proteases, lipases, siderophores and catalase-a major clinical role for these factors has not been demonstrated convincingly in CF [83, 84] . However, catalase is associated with the organism's ability to resist killing by professional phagocytes and to produce serious infection in patients with CGD [85] . [90] , but the significance of limited epithelial invasion by bacteria remains unclear [9 1 3. A recent and potentially seminal publication has even suggested that enhanced uptake of CF pathogens by epithelial cells expressing surface cystic fibrosis transmembrane conductance regulator (CFTR), followed by epithelial desquamation, may be an important host defence mechanism rather than a bacterial virulence determinant [92] .
Intracellular survival
Overall, the role of intracellularity in the pathogenesis of B. cepacia infection in CF patients is still in doubt. As a caveat, the demonstration of its intracellular survival and growth within amoebae , raises the possibility that these free-living protozoa may act as an environmental reservoir from which CF patients could acquire the organism [93] .
B. cepacia and host immune responses
Colonisation with B. cepacia is associated with a pronounced and specific humoral response, including raised serum IgG and IgA and sputum IgA titres against B. cepacia lipopolysaccharide (LPS) and outermembrane protein (OMP) components [87, 94] . Anti-B. cepacia antibodies have also been detected in noncolonised CF patients, and particularly in patients colonised with F aeruginosa [87, 95] . Studies with preabsorbed sera have failed to demonstrate an appreciable degree of cross-reactivity between the two species, either for OMP or LPS components [87, 96] , suggesting that the response to I? aeruginosa is not the source of pre-colonisation anti-B. cepacia antibody. Generally, levels of anti-B. cepacia immunoglobulin in noncolonised patients are low, but the demonstration of substantially raised titres in a subset of patients may reflect previous exposure to B. cepacia where an appropriate antibody response has prevented the occurrence of colonisation. On the other hand, the demonstration of antibody in stored pre-colonisation sera from patients who subsequently became colonised, indicates that antibody does not always play a preventative role. Similarly, the role of antibody in patients once they are colonised is unclear; for example, clinical outcome is independent of the magnitude of anti-B. cepacia responses [87] . A recent study [97] with immunoblotting techniques has suggested that IgG antibodies against a 30-kDa OMP, identified presumptively as the major immunodominant porin, OMP D [95, 98] , are associated with a better prognosis in colonised patients. If these results are confirmed, it raises the possibility of using this OMP as a target for immunotherapy.
The association of B. cepacia with CGD, an inherited defect in neutrophil oxidative killing pathways, and the role of neutrophils as the predominant immune effector cell in the CF lung [99] , have led to speculation that the interaction between B. cepacia and neutrophils may be important in the evasion of host defences by this organism. Speert et al. [85] demonstrated that, unlike I? aeruginosa, B. cepacia is resistant to non-oxidative neutrophil killing mechanisms; hence the role of B. cepacia in CGD. Evasion of the normal neutrophil oxidative burst would aid the survival of B. cepacia in the presence of a pronounced immune response. Within the CF lung, normal opsonisation processes are compromised severely through the disruption of immune effector molecules by bacterial and host proteases [loo, 1011. In particular, cleavage of complement receptors and immunoglobulin molecules within the respiratory tract may neutralise the humoral immune response to B. cepacia and enable the organism to persist in the lungs of colonised patients. However, this observation does not explain the ability of rough, LPS-deficient, serumsensitive B. cepacia to cause invasive pneumonitis and septicaemia in patients with elevated anti-B. cepacia immunoglobulin titres [86] .
Inyammatory damage
Increasing evidence has emerged to suggest that host immune responses are important in the pathogenesis of B. cepacia infection. A UK multicentre study has shown that levels of the inflammatory markers, C- 
Unique bacterial clones and B. cepacia transmission factors
Epidemiological data and genomic fingerprinting suggest that the variable incidence of B. cepacia-in particular, the lack of cross-infection in some centres [75, 81] , and the contrasting epidemic spread in others-reflects the behaviour of a relatively small number of highly transmissible clones [46, 69, 110-1121. It seems reasonable to speculate that B. cepacia strains responsible for epidemic spread may harbour a common colonising factor whose identification could be exploited for diagnostic and therapeutic purposes. At present, the most significant of these factors is adhesion to respiratory mucin [53, , associated with giant intertwined fibres referred to as cable pili [53, 
cepacia colonisation in 38% of UK patients [46] . In a slightly different form, cbl has also been associated with epidemic transfer of B. cepacia from CF to non-CF patients in a Mississippi outbreak [16,69, 1151. However, studies with a cbl DNA probe indicated that cbl is not present in all epidemic clones, suggesting that other bacterial and host factors need to be identified [69] . Interestingly, a recent study [ 1161 has described enhanced binding of the ET12 lineage to lipid receptors, particularly the galactolipid globotriosylceramide (GB3), and led to speculation that upregulation of GB3, mediated through the infection process and TNF stimulation within the lung, may provide an alternative receptor for isolates in which cable pili are poorly expressed and a second receptor system for the epithelial attachment of bacteria that have migrated through the mucosal blanket.
Experimental proof of direct or indirect transmission of epidemic B. cepacia is not feasible and can be judged only by circumstantial evidence. However, epidemiological data has strikingly demonstrated such potential. Colonisation with more than one strain of B. cepacia is unusual and has been reported in <lo% of patients [46] . During the Edinburgh outbreak, PFGE fingerprinting showed that one patient harboured two B. cepacia strains in his respiratory secretions, including the ET12 clone; however, only the epidemic strain was transmitted subsequently to his girlfriend [621.
Modes of transmission and the risks of acquisition
The potential risks of B. cepacia transmission, either directly by person-to-person spread or indirectly from contaminated fomites, continue to be a major concern to the CF community. Table 2 summarises the extensive documented evidence for direct transmission of B. cepacia between CF patients during close contacts within hospitals [61, 63, 651 , at educational or summer camps [59, 66] and through other social contacts [62, 631 ; in contrast, several reliable studies have found no evidence of cross-infection [72-751. In their initial report, LiPuma et al. [59] cited previous failures to culture B. cepacia from respiratory equipment and environmental surfaces as circumstantial evidence that direct person-to-person spread might be the primary means of transmission. However, a subsequent prospective study [ 1 171 with selective culture and DNA-based typing of isolates showed that colonised patients can contaminate their environment; thus indirect transmission might occur via contaminated surfaces. The intrinsic resistance of B. cepacia to many antibiotics also raised justifiable concern that the use of contaminated home-use nebulisers might present a special hazard for B. cepacia acquisition. Currently, evidence for nebuliser-associated transmission is scanty and equivocal. A case-controlled retrospective study of five CF patients undergoing treatment in a CF centre [ 1 181 showed a significant association between outpatient nebuliser use and B. cepacia colonisation. B. cepacia was also cultured from nebulisers used by colonised patients. Unfortunately, no bacterial typing was performed to confirm the clonal relationships of the human and nebuliser isolates. Recently, in a prospective study [ 1193, B. cepacia was cultured from three of 35 home-use nebulisers. DNA macrorestriction analysis by PFGE revealed that one of two strains of B. cepacia recovered from the nebuliser of one patient was also present in the patient's sputum. However, sputum cultures from the two other patients whose nebulisers harboured B. cepacia did not yield the organism, suggesting an environmental origin for the B. cepacia strain isolated from the nebuliser. Other studies of nosocomial acquisition of B. cepacia in non-CF patients have suggested that respiratory infection probably occurred by indirect transmission following use of contaminated nebuliser devices [3 1, 1201. Airborne dissemination may also present a small risk of B. cepacia acquisition. In a prospective study, B. cepacia was recovered from the room air during occupation by five of six patients, but to only a limited extent, with the number of bacteria ranging from 1 to 158 cfu/m3 [ 1211. Maximum yields were associated with episodes of coughing and, after a patient left the room, the organism persisted in room air for up to 45 min.
To conclude, ethical considerations prevent experi- (Tables 2  and 3) , skin contact, respiratory aerosols, sharing food, contaminated equipment, co-habitation or undergoing physiotherapy in the same room as a B. cepaciapositive individual present reasonable risks of acquisition. However, epidemiological evidence [3 8,621, including the high numbers (typically > lo8 cfu/ml) of B. cepacia present in the saliva of colonised patients, suggests that the close and frequent social contact that occurs between siblings, the direct exchange of respiratory secretions associated with kissing, and the involvement of a highly transmissible B. cepacia lineage arguably present the greatest risks of acquisition.
Environmental release of B. cepacia as a biological control agent
Whilst the CF community debates the clinical issues of B. cepacia colonisation and transmission, agricultural microbiologists continue to develop the organism as a biological control agent to exploit its antifungal activity (Fig. 1) We have stated previously that the scientific evidence that environmental strains of B. cepacia present little hazard to man is weak [14] and is based on examination of only a few bacterial isolates and In colonised individuals, B. cepacia saliva counts can exceed 10' cfidml, suggesting that the highest risk of patient-to-patient spread is transmission of respiratory secretions during kissing or through sharing of eating or drinking utensils.
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Spirometer mouthpieces become heavily contaminated during lung function tests. Risk avoided by use of disposable mouthpieces. Recovery from the surface of lung function equipment is low.
Recovery from antibiotic reservoirs of nebulisers has been reported, but incidence is low and the degree of risk appears secondary to the preceding factors. Aerosol recovery is low, suggesting low risk of aerosol transmission.
Hands become contaminated after coughing and the organism can be transmitted by handshake. Survival on hands reduced to 10% after 30 min; this varies in different individuals and may account for variable recovery in surveillance studies.
Gastrointestinal carriage has not been demonstrated, even in colonised individuals, suggesting that the risk of faecal-oral spread is minimal. After surface contamination with B. cepaciu-containing sputum, viable bacteria can be recovered for several weeks. Surface contamination by B. cepucia sputum is eliminated by treatment with UV irradiation and with common hospital disinfectants, including Milton, Dettol, alcohol 70%, phenols, iodine and cetrimide. Careful drying is important after washing or disinfection. Recovery of B. cepacia from soil, plants, drains, lakes and surface waters is low, suggesting that natural environments present a possible but low risk for acquisition. inappropriate bacterial properties [24] . Although some studies have indicated that environmental and clinical isolates are distinct, no reliable phenotypic markers have been identified [25, 45, 1081 . The suggestion that clinical isolates can be distinguished from soil isolates based on the former's lack of plant pathogenicity [45] is discounted by the fact that CF isolates of B. cepacia will readily macerate onion tissue (Fig. 2) [14]. In addition, the invasive B. cepacia foot lesions known as swamp foot [128] , acquired by military personnel during jungle training, confirm the pathogenic potential of environmental strains of B. cepacia for man.
The potential hazard that some or all environmental B. cepacia strains present to the CF community is unclear and requires investigation. The fact that new cases of B. cepacia colonisation continue to occur with strains that show no genotypic relationship to other isolates within the same CF centre, points to the environment as a potential source. However, the extent of this risk is difficult to assess. Extensive microbiological safaris into supermarkets and domestic homes [15] , and a range of botanical soils and cultivars [14] , indicate that B. cepacia can be cultured from up to 20% of warm moist environmental sites, particularly soils, but that it is not as ubiquitous as other pseudomonads. Interestingly, in our studies to date, none of the environmental isolates of B. cepacia have been identified as belonging to genomovar 111.
Conclusions and future prospects
B. cepacia is a striking example of a multiresistant soil saprophyte and phytopathogen that has emerged as an important threat to susceptible human hosts. In the CF community, the degree to which infection control measures should be implemented continues to arouse strong scientific and social debate. The validity of strict control is supported by circumstantial, but nevertheless compelling, evidence for direct person-to-person transmission of epidemic strains through nosocomial and social contact. In contrast, although the risk of indirect iatrogenic spread from contaminated fomites remains unclear, available evidence suggests that this route is less important than direct transfer. An important caveat in attempts to generalise on B. cepacia transmission is evidence that the major epidemics of B. cepacia involve a subpopulation of highly epidemic lineages which might be re-allocated ultimately to new species; ' Burkholderia cfei' might be an appropriate but probably controversial choice! Ongoing microbiological surveillance in CF centres indicates that sporadic acquisition of epidemic lineages continues to occur when there is a failure to comply with infection control measures. For example, a striking demonstration of the continued potential for transmission of the ET12 lineage was its recent acquisition by an Edinburgh CF adult; extensive inquiries suggested that this patient had social contact for only 10 min whilst visiting another CF male who was hospitalised during an episode of B. cepacia septicaemia. Even when infection control appears effective in preventing spread of epidemic lineages, new cases of B. cepacia colonisation continue to occur with isolates that exhibit unique PCR ribotyping or PFGE profiles. Such sporadic acquisitions raise a fundamental question concerning the source and colonising potential of individual B. cepacia strains. For example, does the environment contain a subpopulation of B. cepacia clones that are innately primed for human colonisation, or does colonisation and virulence in man require in-vivo adaptation? Future improvements in laboratory identification of B. cepacia subpopulations associated with CF disease and identification of transmission factors, in addition to cable pili, may provide scientific justification for relaxation of segregation in the absence of known epidemic and potentially virulent lineages. Turning our attention to CF patients, we need to clarify why colonisation by the same strain of B. cepacia leads to variable clinical responses, ranging from asymptomatic colonisation to rapid fatal pulmonary deterioration. It could be argued that this particular problem is not unique to B. cepacia, and that applying Koch's postulates in an attempt to distinguish between sycophancy and pathogenic potential is difficult when dealing with any opportunist pathogen. Certainly, host factors cannot be ignored in attempts to understand the pathogenic processes involved in CF lung infections.
During the final preparation of this review, a deceptively simple and elegant study has illustrated how CFTR-associated defective C1-transport across airway epithelia might lead to bacterial colonisation in CF patients. Smith et al. [ 1291 showed that the normal human apical epithelial surface is bactericidal for P aeruginosa and S. aureus; in contrast, the bactericidal activity was inhibited reversibly in CF epithelia because of a high NaCl concentration. If this phenomenon varies in individual CF patients-or if individual B. cepacia strains differ in susceptibility to the defensin-like bactericidal agent-it might explain some of the host-and pathogen-specific anomalies associated with B. cepacia pulmonary infection and suggest novel strategies therapy of this unusual pathogen.
It is difficult to avoid a that whilst B. cepacia community to ransom, for infection control and and challenging opportunist final comment on the irony continues to hold the CF agricultural microbiologists seek to develop the commercial and beneficial potential of this microbial Jekyll and Hyde in their search for biological control agents. This situation demonstrates the diversity of microbiology, but should also encourage attempts to reduce the present gulf between agricultural and medical science.
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